X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
4D-710 is comprised of a targeted and evolved vector, A101, and codon-optimized microCFTR transgene, to treat patients with cystic fibrosis, independent of specific CFTR mutation, designed for aerosol delivery to achieve CFTR expression within lung airway epithelial cells.
Lead Product(s): 4D-710
Therapeutic Area: Genetic Disease Product Name: 4D-710
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
The Company intends to use the net proceeds to fund its ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-150, 4D-710, 4D-310, 4D-125 and 4D-110. 4D-150 is a dual-transgene, intravitreal gene therapy.
Lead Product(s): 4D-150
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2024
Details:
The Company intends to use the net proceeds to fund its ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-150, 4D-710, 4D-310, 4D-125 and 4D-110. 4D-150 is a dual-transgene, intravitreal gene therapy.
Lead Product(s): 4D-150,Aflibercept
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2024
Details:
4D-710 is comprised of our targeted and evolved next generation vector, A101, and a codon-optimized CFTR transgene. It is under phase 1/2 clinical development for the treatment of cystic fibrosis lung disease.
Lead Product(s): 4D-710
Therapeutic Area: Genetic Disease Product Name: 4D-710
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system (CNS) diseases, including amyotrophic lateral sclerosis (ALS).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Arbor Biotechnologies, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 03, 2024
Details:
4D-150 is an AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept. It is under phase 1/2 clinical development for the treatment of wet age-related macular degeneration.
Lead Product(s): 4D-150
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
4D-310 utilizes the targeted and evolved C102 vector to deliver a functional copy of the GLA gene and was designed to correct the AGA enzyme function within cardiomyocytes. It is currently being investigated for fabry disease.
Lead Product(s): 4D-310
Therapeutic Area: Genetic Disease Product Name: 4D-310
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
4D-150 is comprised targeted and evolved intravitreal vector, R100, and a payload that expresses both aflibercept and a VEGF-C RNAi. This dual transgene payload inhibits 4 angiogenic factors: VEGF A, B, C and PlGF, and is investigated for patients with diabetic macular edema.
Lead Product(s): 4D-150
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
4D-150 is comprised targeted and evolved intravitreal vector, R100, and a payload that expresses both aflibercept and a VEGF-C RNAi. This dual transgene payload inhibits 4 angiogenic factors: VEGF A, B, C and PlGF, and is investigated for patients with diabetic macular edema.
Lead Product(s): 4D-150
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
4D-150 is comprised targeted and evolved intravitreal vector, R100, and a payload that expresses both aflibercept and a VEGF-C RNAi. This dual transgene payload inhibits 4 angiogenic factors: VEGF A, B, C and PlGF.
Lead Product(s): 4D-150
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
